Anticancer-antibiotics

Anticancer Drugs: Antibiotics
  • Clinically useful anticancer antibiotics: derived from Streptomyces
  • These antibiotics act by:
    • DNA intercalation, blocking synthesis of DNA and RNA
  • Anthracyclines: Doxorubicin (Adriamycin, Rubex, Doxil) and Daunorubicin (DaunoXome)
    • IV administration; hepatic metabolism; biliary excretion; some urinary excretion; enterohepatic recirculation.
    • Among the most useful anticancer antibiotics
    • Mechanism of action:
      • DNA intercalation -- blocking synthesis of DNA and RNA; DNA strands scission -- by affecting topoisomerase II
      • Altering membrane fluidity and ion transport
      • Semiquinone free radical an oxygen radical generation (may be responsible for myocardial damage)

Return to main menu

Carcinomas-Doxorubicin
 breast carcinoma  ovarian carcinoma  thyroid carcinoma
 endometrial carcinoma  testicular carcinoma  lung carcinoma

 

Sarcomas-Doxorubicin
 Ewing's sarcoma  osteosarcoma  rhabdomyosarcomas

 

Hematologic Cancers-Doxorubicin
 acute leukemia  multiple myeloma  Hodgkin's disease  non-Hodgkin's lymphoma
  • Adjuvant therapy in: osteogenic sarcoma and breast cancer
  • Generally used in combination protocols with:
    • cyclophosphamide (Cytoxan)
    • cisplatin (Platinol)
    • nitrosoureas
  • Major Use: Acute Leukemia
  • Daunorubicin: limited utility-- limited efficacy in treating solid tumors.
  • Idarubicin: approved for acute myeloid leukemia
    • Idarubicin in combination with cytarabine: more active than daunorubicin in inducing complete remission in acute myelogenous leukemia.
  •  Adverse Effects:
    • Bone marrow depression (short duration)
    • Cumulative, dose-related, possibly irreversible cardiotoxicity.
    • Total, severe alopecia

  • Dactinomycin (Cosmegen)
    • IV administration; 50 percent remains unmetabolized.

    • Mechanism of action: intercalation between guanine-cytosine base pairs

      • inhibits DNA-dependent RNA synthesis

      • blocks protein synthesis

    • Clinical Uses:

      • dactinomycin in combination with vincristine (Oncovin)and surgery (may include radiotherapy) in treatment of Wilms' tumor

      • dactinomycin with methotrexate: maybe curative for localized or disseminated gestational choriocarcinoma.

    •  Adverse Effects:

      •  Major dose limiting toxicity: bone marrow suppression (all blood elements affected -- particularly platelets and leukocytes)

        • occasional severe thrombocytopenia

      • nausea

      • vomiting

      • diarrhea

      • oral ulcers

      • Dactinomycin: immunosuppressive (patient should not receive live virus vaccines)

      • alopecia/skin abnormalities

      • interaction with radiation ("radiation recall")

Return to main menu

  • Mechanism of action:binds to DNA -- interrupts DNA-directed RNA synthesis

    • Also decreases plasma calcium (independent tumor cell action;acts on osteoclasts)

  • Clinical Uses:

    • some efficacy in testicular cancer that is unresponsive to standard treatment:

    • especially useful in managing severe hypercalcemia associated with cancer

  •  Adverse Effects:

    • nausea

    • vomiting

    • thrombocytopenia

    • leukopenia

    • hypocalcemia

    • liver toxicity

    • bleeding disorders

  • Mitomycin: (Mutamycin)

    • Mechanism of action:

      • metabolic activation to produce a DNA alkylating agent.

      • Solid tumor hypoxic stem cells may be more sensitive to the action of mitomycin.

      • Best available drug, in combination with x-rays, to kill hypoxic tumor cells.

    •  Clinical Use:

      • in combination chemotherapy {with vincristine and bleomycin}: squamous sell carcinoma of the cervix

      • adenocarcinoma of the stomach, pancreas, and lung {along with flurouracil and doxorubicin}

      • second-line drug: metastatic colon cancer

      • topical intravesical treatment of small bladder papillomas.

    •  Adverse Effects:

      •  severe myelosuppression, especially after repeated doses, suggest action on hematopoietic stem cells.

      • Vomiting

      • anorexia

      • occasional nephrotoxicity

      • occasional interstitial pneumonitis

  • Mechanism of Action:binds to DNA -- produces single- and double-strand breaks (free radical formation)

    • Cell cycle specific: arrests division in G2

    • Synergistic effects with vinblastine and cisplatin (curative protocol for testicular cancer)

  • Clinical Uses:

    • Testicular cancer

    • Squamous cell carcinoma: head, neck, cervix, skin, penis, and rectum

    • combination treatment: lymphoma

    • intracavity treatment: malignant effusions in ovarian breast cancer

  •  Adverse Effects:

    • Anaphylactoid reaction (potentially fatal)

    • Fever

    • anorexia, blistering, hyperkeratosis (palms)

    • pulmonary fibrosis (uncommon)

    • No significant myelosuppression

Return to main menu

Salmon, S. E. and Sartorelli, A. C. Cancer Chemotherapy, in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, p. 881-911.